Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia.
Level 5 - mechanism / opinion, no new human data
In vitro bench study on cultured human airway epithelia (non-clinical mechanistic research).
PubMed 12805434 · doi:10.1128/jvi.77.13.7361-7366.2003
What was done
Investigators evaluated the mechanisms limiting apical infection and transduction efficiency of recombinant adeno-associated virus serotypes 2 (rAAV-2) and 5 (rAAV-2/5) in polarized human airway epithelia. Using luciferase and enhanced green fluorescent protein (EGFP) reporter vectors, they assessed the effects of the tripeptide proteasome inhibitor LLnL on apical versus basolateral entry pathways. They also compared the transduction of short self-complementary AAV (scAAV) versus full-length conventional single-stranded AAV vectors to determine if second-strand genome synthesis limits apical transduction.
What was found
Coadministration of LLnL significantly enhanced apical transduction for both rAAV-2 and rAAV-2/5. While rAAV-2/5 was slightly more effective than rAAV-2 under basal conditions, rAAV-2 transduction surpassed rAAV-2/5 in the presence of proteasome inhibitors. Basolateral transduction for both serotypes was not significantly affected by LLnL. Transduction rates comparing scAAV to conventional AAV vectors demonstrated that second-strand synthesis was not rate limiting for either serotype and was not altered by LLnL following apical infection. The abstract did not report exact numerical values or effect sizes.
Why it matters
This study shows that intracellular trafficking and ubiquitin-proteasome degradation, rather than viral genome conversion, constitute the primary barrier to apical AAV-mediated airway gene delivery, helping guide vector optimization for pulmonary gene therapy.
Limits
The investigation was restricted to in vitro polarized human airway epithelial cultures without in vivo validation of physiological barriers like mucus clearance or immune responses. Specific sample sizes, replicate counts, quantitative transduction levels, and statistical error metrics were not reported in the abstract.
Cited by
- supports Adeno-associated virus (AAV) does not transfect well through the nasal mucosa.